Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 40

Explainer

Can you freeze a reconstituted peptide?

A reader paused a CJC-1295/ipamorelin cycle and wanted to freeze the rest. Here is what the closest approved label and the freeze-thaw literature say.

20 Aug 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Selank and Semax: Should You Combine Them?

Selank has real generalized anxiety disorder trial data. Semax's focus reputation does not, and no study has combined the two.

20 Aug 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Tirzepatide vs Semaglutide: Liver Risk

A large real-world study found tirzepatide and injectable semaglutide carry the same risk of serious liver outcomes in adults with type 2 diabetes.

20 Aug 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Switching to Tirzepatide: Liver Fibrosis

A Japanese study found switching from other GLP-1 drugs to tirzepatide reduced FIB-4 liver fibrosis scores in high-risk patients.

20 Aug 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Avexitide: the GLP-1 drug that blocks it

Avexitide, Amylyx's investigational GLP-1 receptor blocker, cut severe post-bariatric hypoglycemia events by 55 percent in a phase 3 trial.

19 Aug 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

CagriSema meta-analysis: what it found

Seven pooled CagriSema trials show more weight loss than semaglutide or cagrilintide alone. The combination is still unapproved, and pooled data has limits.

19 Aug 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

ENV-308: a pill built to mimic exercise

Enveda's ENV-308 mimics an exercise-linked metabolite and aims to preserve muscle after GLP-1 weight loss, but its Phase 1 trial tested only safety.

19 Aug 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

GLP-1 Drugs and Ankle Osteoarthritis Care

A 2026 cohort study ties GLP-1 receptor agonist use to fewer ankle injections and replacements, but more arthroscopy in diabetes.

19 Aug 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

GLP-1 drugs and ankle OA: new cohort data

A Johns Hopkins cohort study found obese GLP-1 users had lower rates of ankle injection and arthroplasty. Diabetic users showed higher arthroscopy rates.

19 Aug 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Hunger pain: semaglutide in schizophrenia

A qualitative study asked people with schizophrenia how semaglutide changed the hunger antipsychotics can cause.

19 Aug 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Semaglutide lowers hsCRP in SELECT

A Circulation analysis of SELECT finds semaglutide 2.4 mg reduces hsCRP in adults with prior heart attack or stroke. What it means, and what it doesn't.

19 Aug 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Sleep and mood after starting GLP-1 drugs

A new observational study links tirzepatide and semaglutide to improved sleep and depression scores at three months, with caveats.

19 Aug 2026 · PeptideMethods Editorial Team · 4 min read